News in Brief
Pharmacology - Dec 4
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
wire - news in brief
Category
Results 1 - 50 of 420.
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 Chronic graft-versus-host disease (GvHD) is a life-threatening complic
Strong and resilient supply chains ensure the provision of quality health products and vaccines to patients, making them a central component of health systems.
ETH Zurich supports art in construction, and, as part of a project competition, has selected art projects by Maya Rochat and Yves Netzhammer that take an innovative approach to reflecting on teaching and research in the two ETH buildings BSS and ML-FHK.
Engineers from the ETH Feasibility Lab are working together with the ICRC to develop a prosthetic leg that allows easy replacement of its wearing part.
If innovative projects and achievements in technology transfer stand out, they should be honored accordingly.
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif
Elecsys Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein The spike protein is the target of many COVID-19 vaccines in development This test may help identif
Roberto Gargiani, an architectural historian and professor at EPFL, has penned a new history of concrete in the United States from 1940 to 1970.
The analysis of DNA fragments and their assignment to individual species - an increasingly well-established approach - is transforming biodiversity assessment. Samples collected from waterbodies permit rapid biomonitoring of aquatic ecosystems. However, environmental DNA (eDNA) analysis is not without pitfalls.
During the lockdown last spring, Julian Ferchow put his doctoral project aside to help relieve the strain on hospitals.
Bread wheat can grow in highly diverse regional environments. An important reason for its great genetic variety is the cross-hybridization with many chromosome fragments from wild grasses. This is shown by the genome sequences of 10 wheat varieties from four continents, which an international consortium including researchers from the University of Zurich has now decoded.
ETH Zurich intends to further expand its leading position in quantum research, and so it is planning a highly specialised physics laboratory building on the Hönggerberg campus.
Iron-deficiency anaemia is a major concern in low income countries, especially for women. A study conducted in Tanzania has now demonstrated the advantage of iron infusion therapy over the usual treatment with iron tablets.
Tackling pandemic threats proactively
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.
If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.
The gravity of dreams
Why is gravity the most mysterious force of nature? Lavinia Heisenberg studies how the universe was formed, and how it is changing.
Why is gravity the most mysterious force of nature? Lavinia Heisenberg studies how the universe was formed, and how it is changing.
At Eawag, the aquatic research institute, numerous scientists are conducting research into toilets. In short videos, seven of them explain what fascinates them about the topic and what exactly their research is all about.
A new exhibition in the Ethnographic Museum of the University of Zurich delves into the recent history of the Ayoréode, a nomadic people in the forests of Bolivia, who have had to adapt to settled life for decades.
An international study led by the University of Bern has investigated the effects of ambient Particulate Matter (PM) from human and natural sources on human lung cells.
Coronavirus: simplified, faster generation of SwissCovid app codes
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.
The process of generating covidcodes has been significantly simplified and accelerated. Persons who have tested positive can enter their code into the SwissCovid app to inform other app users of possible exposure to the virus.
Three spin-offs make the finals of a deep tech startup competition
Three EPFL spin-offs - CompPair, Hydromea and Nanogence - have made it through to the finals of the Hello Tomorrow Global Challenge, an international startup competition that is being held virtually this year.
Three EPFL spin-offs - CompPair, Hydromea and Nanogence - have made it through to the finals of the Hello Tomorrow Global Challenge, an international startup competition that is being held virtually this year.
Sustainable high-tech materials are expensive. However, this may soon change. Through his ETH Pioneer Fellowship, Christoph Schneeberger is developing a process that enables more efficient production of fibre-reinforced plastics.
Cybathlon Moves Despite Distance
Today was the last day of the Cybathlon 2020 Global Edition. In total, 51 teams from 20 countries competed against each other, completing everyday tasks with the help of state-of-the-art assistance systems.
Today was the last day of the Cybathlon 2020 Global Edition. In total, 51 teams from 20 countries competed against each other, completing everyday tasks with the help of state-of-the-art assistance systems.
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult p
Results from real-world data and post-hoc analysis of Novartis Beovu pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commi
In the journal ZooKeys, a group of scientists from Eawag and Bern University have described seven whitefish species endemic to the Bernese Oberland lakes - including four not previously described scientifically, two of which have only been identified as distinct species in the last few years.
The results of a survey conducted by the University of Basel showed that the pandemic's first wave put a great deal of psychological strain on many people in Switzerland.
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
News in Brief
Pharmacology - Dec 4
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD
Novartis announces first data from REACH3 trial showing Jakavi (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD